Triple-negative breast cancer (TNBC) is aggressive and presents unique clinical challenges and limited treatment options due to the absence of the targetable estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) [8]. Here, ESR1 is linked to triple-negative breast carcinoma.